<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24979">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798914</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-139</org_study_id>
    <nct_id>NCT01798914</nct_id>
  </id_info>
  <brief_title>Patient Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder</brief_title>
  <official_title>Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to allow patients with specific needs for inhaled insulin to
      continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn
      from the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of
      subjects currently using Exubera to treatment with TI Inhalation Powder
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The main objective of this trial is to monitor safety  outcomes and collect safety information on TI Inhalation Powder in subjects whose treatment has been converted from Exubera to TI Inhalation Powder.</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables monitored will include all adverse events (AEs)and serious adverse events (SAEs)- throughout trial duration</measure>
    <time_frame>72 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination findings</measure>
    <time_frame>Every 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>Every 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chest x-rays</measure>
    <time_frame>Annually</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Tests - spirometry (FEV1, FVC and FEV1/FVC)</measure>
    <time_frame>Every six months up to month 60 then annually</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Tests- DLco</measure>
    <time_frame>Every six months up to month 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Tests - TLC</measure>
    <time_frame>Every six months up to month 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be analyzed utilizing a listing with descriptive statistics, where applicable</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Technosphere® Insulin (TI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation Powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin (TI) Inhalation Powder</intervention_name>
    <description>Inhalation Powder</description>
    <arm_group_label>Technosphere® Insulin (TI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or
             has been treated with Exubera.

          -  Subject has a severe phobia to sc injections of insulin (needle phobia) preventing
             conventional treatment OR has impaired sc insulin absorption

        Exclusion Criteria:

          -  Smoking in the previous 6 months

          -  History of asthma or chronic obstructive pulmonary disease (COPD) or any other
             significant pulmonary disease, or exposure to pulmonary toxins.

          -  Clinically significant pulmonary abnormalities on chest high-resolution computed
             tomography (HRCT).

          -  PFT results prior to transferring to TI Inhalation Powder showing any of the
             following: FEV1 &lt; 70% of predicted, FVC &lt; 70% of predicted, DLCO &lt; 70% of predicted,
             TLC &lt; 80% of predicted.

          -  Allergy to insulin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norton</city>
        <state>Massachusetts</state>
        <zip>02766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>February 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
